Ikena Oncology Inc
NASDAQ:IKNA
Ikena Oncology Inc
Revenue
Ikena Oncology Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ikena Oncology Inc
NASDAQ:IKNA
|
Revenue
$9.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Ikena Oncology Inc's Revenue?
Revenue
9.2m
USD
Based on the financial report for Dec 31, 2023, Ikena Oncology Inc's Revenue amounts to 9.2m USD.
What is Ikena Oncology Inc's Revenue growth rate?
Revenue CAGR 5Y
56%
Over the last year, the Revenue growth was -41%.